NCT07297693

A Study to Evaluate the Pharmacokinetics and Safety Between HIP2503 and HCP1306 in Healthy Volunteers

An Open-label, Randomized, Single-dose, Oral Administration, 2-sequence, 2-period, Crossover Study to Evaluate the Pharmacokinetics and Safety Between HIP2503 and HCP1306 in Healthy Subjects

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: All
• Age: 19 Years – 64 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HIP2503 and HCP1306 in healthy volunteers.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	HIP2503	Take 1 orally disintegrating tablet once per period
DRUG	HCP1306	Take 1 tablet once per period

Timeline

• Start date: 2025-12-19
• Primary completion: 2026-03-25
• Completion: 2026-04-10
• First posted: 2025-12-22
• Last updated: 2025-12-22

Locations

1 site across 1 country: South Korea